[Antibodies to neuroleptics and their role in the mechanisms of the development of drug resistance in psychopharmacotherapy of patients with paranoid schizophrenia].
A study was made of the content of drug antibodies (DAT) to chlorpromazine, triphthazine and haloperidol in the blood sera of 112 patients with paranoid schizophrenia (acute period, curable exacerbation associated with the chronic course, and a group of therapeutically resistant subjects). Antibodies to neuroleptics were demonstrable in all the patients' groups. However, the rate of positive reactions and the content of DAT in the therapeutically resistant patients differed significantly from the characteristics in "acute" patients and in the group of "nonresistant" ones. The maximum "antigenicity" was shown by chlorpromazine, the minimum by haloperidol. The appearance and the content of DAT agree well with the duration of the drug intake, especially if the treatment is repeated. In acute conditions, the content of DAT was found to depend on the increment of the daily dose (with the exception of haloperidol). In chronic conditions and repeated treatments, the rise of the content of DAT was feasible with the low daily doses, particularly to chlorpromazine.
Govorin
N V
NV
Lozhkina
A N
AN
D000328:Adult; D001323:Autoantibodies / Q000096:biosynthesis*; D002746:Chlorpromazine / Q000008:administration & dosage* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000276:immunology; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors
D001323:Autoantibodies; D006220:Haloperidol; D002746:Chlorpromazine
Antitela k neĭroleptikam i ikh rol' v mekhanizmakh formirovaniia terapevticheskoĭ rezistentnosti pri psikhofarmakoterapii bol'nykh paranoidnoĭ shizofrenieĭ.